A Phase II Evaluation of BAY 43-9006 (Sorafenib, Nexavar®, NCI-Supplied Agent, NSC #724772) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
Phase of Trial: Phase II
Latest Information Update: 22 May 2015
At a glance
- Drugs Sorafenib (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 23 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Aug 2005 New trial record.